Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Lonza Buying Arch Chemicals for $1.2B in Cash

By Pharmaceutical Processing | July 11, 2011

NEW YORK
(AP) — Swiss specialty chemicals and biotechnology company Lonza Group Ltd.
said Monday it will buy Arch Chemicals Inc., a maker of antibacterial products,
for $1.2 billion in cash.

The deal values the Norwalk,
Connecticut, company at $47.20
per share, and also includes $170 million in debt. Lonza will start a tender
offer for Arch Chemicals shares by Friday, and it expects to complete the
acquisition later in 2011. The board of directors of Arch Chemical voted in
favor of the sale and recommended shareholders tender their shares in support.

Lonza said it will have about $1.6 billion in annual revenue
from sales of bacteria-killing products, making it one of the leaders in that
market. Arch Chemicals reported $1.38 billion in revenue in 2010, and Lonza
said $1.2 billion of that total came from sales of products used to kill
harmful bacteria in water, in industrial applications, for wood protection, and
for personal care. Lonza said the market for antibacterial products is growing
steadily and is worth about $10 billion per year.

Shares of Arch Chemicals surged 11 percent Friday despite
weak economic news, and the stock gained another $4.70, or 11 percent, to
$46.87 in morning trading while the broader markets slid. The stock hit a
52-week high of $46.99 earlier in the session and has traded as low as $29.29
over the past year. Lonza said it is offering a premium of 36.7 percent to the
stock’s average closing price over the last 30 days.

Arch Chemicals has approximately 3,000 employees and 23
manufacturing and research sites. Lonza spokesman Dominik Werner told The
Associated Press some jobs will be shed after the deal closes. Werner said any
job cuts would probably come from administration and would not affect
production.

“A good part of the cost reduction is based on the fact
that we’re combining two corporations and so we don’t need the corporate
overhead of Arch,” he said. “There will certainly be job reductions
there, but how much and when is still open.”

Lonza shares were down 0.1 percent at 66.75 Swiss francs
($80.04) on the Zurich
exchange by mid-afternoon.

 

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE